Connect your AI

Stoke Therapeutics, Inc. STOK Price / book

Price / book at other companies

Ionis PharmaceuticalsIONS

25.2×+15.2×

Jazz PharmaceuticalsJAZZ

2.6×+0.8×

Xenon PharmaceuticalsXENE

4.1×+0.5×

Praxis Precision Medicines, Inc.PRAX

6.4×+4.6×

Harmony Biosciences Holdings, Inc.HRMY

1.8×-0.9×

Nurix Therapeutics, Inc.NRIX

3.4×+1.0×

Other financials

Income statement

Revenue$6.2M-96.1%

Operating income-$53.4M-148%

Net income-$50.0M-144%

EPS (diluted)-$0.79-142%

Balance sheet

Cash & equivalents$155.7M-43.4%

Total debt$3.4M-42.5%

Total equity$394.9M+12.8%

Total assets$443.3M+8.9%

Cash flow

Operating cash flow-$60.6M-146%

CapEx$353.0K+132%

Free cash flow-$60.9M-146%

Valuation

Market cap$1.94B+436%

Enterprise value$1.79B+1,855%

P/S60.4×+58.5×

Profitability

Operating margin-577.5%-597pp

Net margin-529.2%-556pp

FCF margin36.2%+18.4pp

Returns & leverage

Return on equity-45.6%-66.1pp

Debt / equity0×0.0×

Current ratio9×+0.6×

Where this comes from

Calculated from Stoke Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=4.9×

Based on the most recent quarter.

The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Stoke Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Stoke Therapeutics, Inc.'s price / book?: Stoke Therapeutics, Inc. (STOK) reported price / book of 4.9× in Q1 2026.
How has Stoke Therapeutics, Inc.'s price / book changed year-over-year?: Stoke Therapeutics, Inc.'s price / book increased by 374.8% year-over-year, from 1× to 4.9×.
What is the long-term trend for Stoke Therapeutics, Inc.'s price / book?: Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s price / book has grown at a -8.4% compound annual growth rate (CAGR), from 8× to 5.1×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.